Cassava Proceeds With Pivotal Phase 3 Program of Simufilam in Alzheimer’s

 

• 1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia.
• Top-line results for on-going, 52-week Phase 3 trial expected approximately year-end 2024.
• Top-line results for on-going, 76-week Phase 3 trial expected approximately mid-year 2025.

https://www.biospace.com/article/releases/cassava-sciences-completes-enrollment-for-pivotal-phase-3-program-of-simufilam-in-alzheimer-s-disease/